Exploring the Past and Current Landscape of Biomarker-Driven Clinical Trials Through Large Language Models

Abstract

A survey of our clinical genomics showed that many individuals likely have mutations that would make them eligible for biomarker-driven trials. We used the NCI Clinical Trials database to show that the distribution of biomarker trials across the United States limits access for many patients and likely leads to the frequent trial termination because of inadequate accrual. Finally, we built an automated publicly available tool that can improve patient-to-trial biomarker-based matching.

Ähnliche Arbeiten